XTalks

OCTOBER 12, 2021

Ritu Chakravarti, assistant professor in the UToledo College of Medicine and Life Sciences, and the paper’s lead author, was investigating 14-3-3? They found that removal of the protein using gene editing technology led to severe early onset arthritis as well as bone loss in two rat models. With the finding that 14-3-3?

Vaccination 105

Vaccination Vaccine Research Immune Response 105

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 76

Drugs Life Science Gene Therapy Genome 76

Drug Discovery World

JANUARY 9, 2024

2024 is anticipated to be a transformational year for the pharma industry, with new modalities like antibody drug conjugates and AI/machine learning providing therapies for patients with limited treatment options.

Drugs 69

Drugs Gene Editing Antibody Medicine 69

XTalks

NOVEMBER 30, 2023

These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV. In 2021, the FDA granted approval to San Francisco-based Excision BioTherapeutics to start trials assessing CRISPR gene editing as a potential treatment for HIV. In November 2023, Hookipa Pharma Inc.,

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

pharmaphorum

JULY 1, 2021

Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, says Debiopharm’s Tanja Dowe. Here are my key takeaways from SynBioBeta’s conference.

Gene Editing 88

Gene Editing Engineer Development Gene 88

Drug Discovery World

NOVEMBER 16, 2022

In April 2021, life sciences solutions provider Molecular Devices launched its Organoid Innovation Centre (OIC), an initiative designed to help scientists leverage the potential of 3D biology throughout the drug discovery process. . The overall response to Covid-19 in the scientific community has been nothing short of amazing right?”

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

Drug Discovery World

MAY 29, 2024

A recent study led by Stanford Medicine and senior author Dr William Robinson notes that 99% of MS patients have EBV antibodies in their blood, indicating prior infection. “Studies have found that EBV triggers a range of very serious health conditions including certain cancers and multiple sclerosis.

Drugs 52

Drugs Gene Editing Life Science Genome 52

XTalks

AUGUST 2, 2023

2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). billion in 2022, a 32.44

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Drug Discovery World

NOVEMBER 30, 2023

The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. It was presented by Lei Shi, PhD, Senior Vice President, R&D, Biointron Biological, titled: ‘Accelerating early discovery through HTP and high-speed antibody production’.

Antibody 59

Antibody Protein Engineer In-Vivo 59

XTalks

JANUARY 4, 2024

The adeno-associated viral (AAV) vector-based gene therapy received approval in Canada for the treatment of adults aged 18 years or older with moderately-severe to severe hemophilia B who are negative for neutralizing antibodies to variant AAV serotype Rh74, Pfizer Canada revealed in its announcement of the approval.

Gene Therapy 111

Gene Therapy Gene Gene Editing Sales 111

Drug Discovery World

JULY 18, 2023

While type II (Cas9) is mainly used for gene-editing applications, CRISPR detecting tools primarily rely on type V (Cas12) and type VI (Cas13) collateral activity. Another promising approach consists of conjugating antibodies, such as an anti-CD38, to the LNPs for targeted delivery into specific tissues.

DNA 98

DNA Genome Genomics RNA 98

XTalks

DECEMBER 24, 2020

The pandemic propelled the life science and healthcare sectors onto center stage, and they rose to the occasion against the most unprecedented health challenge in recent times. While COVID-19 has undoubtedly been the biggest story in the life science industry in 2020, it was a busy and positive year in many other areas.

Life Science 111

Life Science Vaccination Vaccine Gene 111

Drug Discovery World

OCTOBER 7, 2022

It is about going faster in progressing our innovation to market, taking things further along the value chain as we de-risk the early science. It’s about working together with our partners in the life science sector to get world class innovations to patients. . Hamish Ryder.

HR 52

HR Research Drugs Development 52